admin – Page 3753 – Get News Story

CAR-T Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “CAR-T Pipeline Insight 2025” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in CAR-T pipeline landscape. It covers the CAR-T pipeline drug profiles, including clinical and nonclinical stage products. It also covers the CAR-T pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive CAR-T pipeline products in this space.

Explore our latest breakthroughs in CAR-T Research. Learn more about our innovative pipeline today! @ CAR-T Pipeline Outlook

Key Takeaways from the CAR-T Pipeline Report

In March 2025, BeiGene announced a study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of sonrotoclax plus zanubrutinib versus zanubrutinib plus placebo.
In March 2025, Celgene announced a study is to compare the effectiveness and safety of golcadomide in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy vs placebo in combination with R-CHOP chemotherapy in participants with previously untreated high-risk large B-cell lymphoma (LBCL).
In March 2025, Hoffmann-La Roche announced a study is to compare the efficacy and safety of glofitamab in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) vs Pola-R-CHP in participants with previously untreated CD20-positive large B-cell lymphoma (LBCL).
In March 2025, Allogene Therapeutics announced a study in adult patients who have completed standard first line of therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ Investigational Use Only (IUO) MRD test, powered by PhasED-Seq™. The purpose of the trial is to assess the efficacy and safety of consolidation with cemacabtagene ansegedleucel (cema-cel), an allogeneic CD19 CAR T product, as compared to standard of care observation.
In March 2025, Regeneron Pharmaceuticals announced a study study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on patients with previously treated aggressive B-cell non-Hodgkin lymphoma whose cancer has stopped responding to treatment (also known as ‘refractory’) or has returned (also known as ‘relapsed’). The aim of the study is to see how safe, tolerable and effective the study drug is when given alone.
In March 2025, Genmab announced a phase 3, Multicenter, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared to Rituximab Plus Gemcitabine and Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
DelveInsight’s CAR-T pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for CAR-T treatment.
The leading CAR-T Companies such as Caribou Biosciences, Allogene Therapeutics, Synthekine, Shanghai Simnova Biotechnology, Sana Biotechnology, Zhejiang University, Janssen Research & Development, Beijing Immunochina Medical Science & Technology, M.D. Anderson Cancer Center, SecuraBio, CARsgen Therapeutics, Atara Biotherapeutics, Wugen, Vor Biopharma, Juventas Cell Therapy, Hebei Senlang Biotechnology, Cellular Biomedicine Group, Oncternal Therapeutics, Autolus Limited, Lyell Immunopharma, Gracell Biopharmaceuticals, and others.
Promising CAR-T Therapies such as IM23, C-CAR066, AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells, Fludarabine, Cyclophosphamide, and others.

Stay informed about the cutting-edge advancements in CAR-T treatments. Download for updates and be a part of the revolution in care @ CAR-T Clinical Trials Assessment

CAR-T Emerging Drugs Profile

Descartes-08: Cartesian Therapeutics

Descartes-08 is an autologous anti-B cell maturation antigen (BCMA) mRNA CAR-T. Compared to conventional DNA-based CAR T-cell therapies, mRNA CAR-T is designed not to require preconditioning chemotherapy, has been observed to have predictable and controllable pharmacokinetics, and is designed to avoid the risk of genomic integration. Descartes-08 has been granted Orphan Drug Designation by the US FDA for the treatment of MG, a chronic autoimmune disorder that causes disabling muscle weakness and fatigue. Currently, the drug is in Phase II stage of clinical trial for the treatment of autoimmune disorders.

KYV-101: Kyverna Therapeutics

KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate for use in B cell-driven autoimmune diseases. The CAR in KYV-101 was designed by the National Institutes of Health (NIH) to improve tolerability and tested in a 20-patient Phase 1 trial in oncology. Results were published by the NIH in Nature Medicine3. KYV-101 is currently being evaluated in sponsored, open-label, Phase 1/2 trials of KYV-101 in patients with lupus nephritis, an autoimmune disease in which more than half of patients do not achieve a complete response to current therapies and are at risk of developing kidney failure. Additionally, FDA’s IND clearance has been obtained for Phase 2 trials of KYV-101 for multiple sclerosis and myasthenia gravis, and a Phase I/II trial for systemic sclerosis.

TX200: Sangamo Therapeutics

TX200 is composed of the patient’s own (autologous) regulatory T cells (Tregs) engineered to express a chimeric antigen receptor (CAR) designed to recognize the HLA-A2 protein present on a transplanted kidney and bind to it. TX200 is in development for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation from a living donor. It is in Phase I/II stage of its clinical trial.

ALLO-605: Allogene Therapeutics

ALLO-605, a next-generation AlloCAR T™ known as a TurboCAR™, is an investigational product that targets the B-cell maturation antigen (BCMA) for the treatment of patients with relapsed/refractory multiple myeloma and other BCMA-positive malignancies. This study uses ALLO-647, Allogene’s proprietary monoclonal antibody (mAb), as a part of its differentiated lymphodepletion regimen. ALLO-605 incorporates Allogene’s proprietary TurboCAR technology, which allows for cytokine activation signaling to be engineered selectively into CAR T cells. In June 2021, ALLO-605 was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of relapsed/refractory multiple myeloma. The Phase 1 study evaluating ALLO-605 is underway. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Multiple Myeloma.

ATA3219: Atara Biotherapeutics

ATA3219 combines the natural biology of unedited T cells with the benefits of an allogeneic therapy. It consists of allogeneic Epstein-Barr virus (EBV)-sensitized T cells that express a CD19 CAR construct for the treatment of CD19+ relapsed or refractory B-cell malignancies, including B-cell non-Hodgkin’s lymphoma and B-cell mediated autoimmune diseases including systemic lupus erythematosus (SLE) with kidney involvement (lupus nephritis [LN]). ATA3219 has been optimized to offer a potential best-in-class profile, featuring off-the-shelf availability. Currently, the drug is in Phase I stage of its clinical trial.

CB-010 : Caribou Biosciences

CB-010 is an allogeneic anti-CD19 CAR-T cell therapy for the treatment of patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). CB-010 is the first allogeneic CAR-T cell therapy, to our knowledge, in a clinical trial with a PD-1 knockout, a genome-editing strategy designed to improve antitumor activity by limiting premature CAR-T cell exhaustion. CB-010 is being evaluated in the ongoing, open-label, multicenter ANTLER Phase I clinical trial in adults with r/r B-NHL.

The CAR-T Pipeline Report Provides Insights into

The report provides detailed insights about companies that are developing therapies for the treatment of CAR-T with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for CAR-T Treatment.
CAR-T Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
CAR-T Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the CAR-T market

Learn more about CAR-T Drugs opportunities in our groundbreaking CAR-T Research and development projects @ CAR-T Unmet Needs

CAR-T Companies

Caribou Biosciences, Allogene Therapeutics, Synthekine, Shanghai Simnova Biotechnology, Sana Biotechnology, Zhejiang University, Janssen Research & Development, Beijing Immunochina Medical Science & Technology, M.D. Anderson Cancer Center, SecuraBio, CARsgen Therapeutics, Atara Biotherapeutics, Wugen, Vor Biopharma, Juventas Cell Therapy, Hebei Senlang Biotechnology, Cellular Biomedicine Group, Oncternal Therapeutics, Autolus Limited, Lyell Immunopharma, Gracell Biopharmaceuticals, and others.

CAR-T pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

CAR-T Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Discover the latest advancements in CAR-T treatment by visiting our website. Stay informed about how we’re transforming the future of disease @ CAR-T Market Drivers and Barriers, and Future Perspectives

Scope of the CAR-T Pipeline Report

Coverage- Global
CAR-T Companies- Caribou Biosciences, Allogene Therapeutics, Synthekine, Shanghai Simnova Biotechnology, Sana Biotechnology, Zhejiang University, Janssen Research & Development, Beijing Immunochina Medical Science & Technology, M.D. Anderson Cancer Center, SecuraBio, CARsgen Therapeutics, Atara Biotherapeutics, Wugen, Vor Biopharma, Juventas Cell Therapy, Hebei Senlang Biotechnology, Cellular Biomedicine Group, Oncternal Therapeutics, Autolus Limited, Lyell Immunopharma, Gracell Biopharmaceuticals, and others.
CAR-T Therapies- IM23, C-CAR066, AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells, Fludarabine, Cyclophosphamide, and others.
CAR-T Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
CAR-T Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of CAR-T Pipeline on our website @ CAR-T Emerging Drugs and Companies

Table of Content

Introduction
Executive Summary
CAR-T: Overview
Pipeline Therapeutics
Therapeutic Assessment
CAR-T– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Drug name: Company name
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Descartes-08: Cartesian Therapeutics
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
ATA3219: Atara Biotherapeutics
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
CAR-T Key Companies
CAR-T Key Products
CAR-T- Unmet Needs
CAR-T- Market Drivers and Barriers
CAR-T- Future Perspectives and Conclusion
CAR-T Analyst Views
CAR-T Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: CAR-T Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

Future Electronics Launches Digital Campaign Showcasing Wurth Elektronik WE-MXGI SMT Power Inductors

Future Electronics is featuring Wurth Elektronik WE-MXGI SMT Power Inductors in a recently launched digital campaign.

Montreal, Canada – March 24, 2025 – Future Electronics, a global leading distributor of electronic components, is pleased to announce the launch of a new digital campaign highlighting the Wurth Elektronik WE-MXGI SMT Power Inductors. This campaign showcases the exceptional performance and advanced design of the WE-MXGI series, engineered for high-frequency power applications.

The Wurth Elektronik WE-MXGI SMT Power Inductors feature an innovative iron alloy material combined with an optimized wire geometry, delivering ultra-low DC resistance (RDC) and minimal AC losses. This results in superior efficiency and high current capability, all within a compact footprint. Additionally, the inductors’ magnetically shielded construction minimizes electromagnetic interference (EMI), making them ideal for space-constrained designs.

Optimized for switching frequencies beyond 1 MHz, the WE-MXGI series is particularly well-suited for next-generation DC/DC converters utilizing advanced GaN and SiC transistor technologies. These inductors are widely employed in high-current power supplies, FPGA power management, and point-of-load (POL) converters. They are also a preferred solution for battery-powered and portable devices such as PDAs, digital cameras, and smartphones, as well as mainboards, graphic cards, and wireless communication devices.

With an operating temperature range of -40°C to 125°C, the WE-MXGI inductors ensure durability and stable performance across various environmental conditions, making them a reliable choice for demanding power applications.

Future Electronics’ digital campaign will provide engineers and designers with in-depth resources, product specifications, and technical insights to help them integrate Wurth Elektronik’s WE-MXGI inductors into their designs.

For more information about Wurth Elektronik WE-MXGI SMT Power Inductors and to explore the latest digital campaign, visit www.FutureElectronics.com/resources/featured-products/wurth-elektronik-we-mxgi-smt-power-inductors.

About Future Electronics

Founded in 1968, Future Electronics is a global leader in the electronic components industry. Future Electronics’ award-winning customer service, global supply chain programs and industry-leading engineering design services have made the company a strategic partner of choice.

Headquartered in Montreal, Canada, Future Electronics operates in 159 offices across 44 countries with over 5,000 employees. Its worldwide presence powers the company’s outstanding service and efficient, comprehensive global supply chain solutions. Future Electronics is globally integrated and supported by one IT infrastructure which provides real-time inventory availability and enables fully integrated operations, sales and marketing services worldwide. In 2024, Future became a WT Microelectronics company, now dual-headquartered in both Montreal, Canada and Taipei City, Taiwan.

Future Electronics’ mission is always to Delight the Customer®. For more information visit www.FutureElectronics.com.

Media Contact
Company Name: Future Electronics
Contact Person: Jamie Singerman
Email: Send Email
Phone: 514-694-7710
Address:237 Hymus Boulevard
City: Pointe Claire
State: Quebec
Country: Canada
Website: https://www.futureelectronics.com/

Nest And Care Enhances Support for Family Caregivers with Respite Care for the Elderly in Silver Spring

Providing family caregivers a much-needed break while ensuring quality care for their elderly loved ones.

Silver Spring, MD – Nest And Care, a trusted provider of elderly care services in Silver Spring, announces its continued commitment to supporting family caregivers by offering access to respite care for the elderly in Silver Spring. With increasing demands placed on caregivers, the organization aims to deliver tailored care solutions that allow families to rest and recharge, knowing their loved ones are in capable hands.

“At Nest And Care, we understand the emotional and physical toll caregiving can have on families. Our respite care services are designed to offer relief for caregivers and high-quality, compassionate support for their elderly loved ones,” said Kat Villanueva, owner of Nest And Care. “Our mission is to create a trusted care environment that ensures both families and their loved ones feel supported and valued every step of the way.”

The demand for reliable elderly care has grown significantly in Silver Spring, where many families juggle the dual responsibilities of work and caregiving. Nest And Care’s respite care services are crafted to address this need, providing personalized care that ensures seniors receive attention that aligns with their unique requirements. Whether short-term or ongoing, these services are a lifeline for families seeking balance and peace of mind.

Respite care is an essential resource for families facing the challenges of caregiving. Prolonged caregiving without breaks can lead to burnout, increased stress, and compromised physical and mental health. Respite care gives caregivers the time to recharge, tend to personal responsibilities, or simply rest, allowing them to return to their duties feeling rejuvenated and more focused.

In addition to benefiting caregivers, respite care ensures that elderly loved ones receive consistent, professional attention during a caregiver’s absence. This service bridges the gap, preventing disruptions in care routines and ensuring seniors enjoy the quality of life they deserve. With experienced caregivers who provide a supportive and engaging environment, respite care fosters the well-being of elderly individuals.

Considering respite care also strengthens family relationships. When caregivers can step back and prioritize self-care, they are better equipped to maintain healthy and positive interactions with their loved ones. This service provides families with the peace of mind that their loved ones are cared for by skilled professionals, allowing for a deeper focus on quality time and meaningful connections.

For families in Silver Spring seeking exceptional respite care services, Nest And Care stands ready to help. To learn more about the company and its respite care Silver Spring services, visit its website at https://nestandcare.com.

About Nest & Care:

Nest And Care is a leading provider of elderly care services in Silver Spring, MD. Dedicated to enhancing the quality of life for seniors and their families, the organization offers various services tailored to the community’s diverse needs. From respite care to comprehensive elderly care solutions, Nest And Care is committed to delivering personalized, compassionate, and professional support that ensures peace of mind for families.

Media Contact
Company Name: Nest And Care
Contact Person: Kat Villanueva
Email: Send Email
Phone: +1 213 448 9798
Address:10411 Motor City Dr Suite 325
City: Bethesda
State: Maryland 20817
Country: United States
Website: https://nestandcare.com

Neurofibromatosis Type 2 Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Recursion Pharma, Vivace Therapeutics, Healx Limited, SpringWorks Therapeutics

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Neurofibromatosis Type 2 pipeline constitutes 5+ key companies continuously working towards developing 5+ Neurofibromatosis Type 2 treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Neurofibromatosis Type 2 Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Neurofibromatosis Type 2 Market.

The Neurofibromatosis Type 2 Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Neurofibromatosis Type 2 Pipeline Report:

Companies across the globe are diligently working toward developing novel Neurofibromatosis Type 2 treatment therapies with a considerable amount of success over the years.
Neurofibromatosis Type 2 companies working in the treatment market are Recursion Pharmaceuticals, Vivace Therapeutics, Healx Limited, SpringWorks Therapeutics, AstraZeneca, Fosun Pharmaceutical, NFlection Therapeutics, Inc., and others, are developing therapies for the Neurofibromatosis Type 2 treatment

Emerging Neurofibromatosis Type 2 therapies in the different phases of clinical trials are- REC-2282, VT3989, HLX-1502, Mirdametinib (PD-0325901), Selumetinib, FCN-159, NFX-179 Gel, and others are expected to have a significant impact on the Neurofibromatosis Type 2 market in the coming years.
In February 2025, SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company specializing in rare diseases and cancer, announced the online publication of data from the pivotal Phase 2b ReNeu trial in the Journal of Clinical Oncology (JCO). The trial evaluated mirdametinib, an investigational MEK inhibitor, in adult and pediatric patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN). Previously, findings from the multi-center, single-arm ReNeu trial were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
In November 2024, Alexion, AstraZeneca Rare Disease, and Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, announced positive topline results from the Phase 3 KOMET trial. This global, randomized, double-blind, placebo-controlled multicenter study is the largest of its kind in adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas (PN). The findings revealed that KOSELUGO, an oral and selective MEK inhibitor, achieved a statistically significant and clinically meaningful improvement in objective response rate (ORR), the primary endpoint, compared to placebo in these patients.
In November 2024, SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company specializing in severe rare diseases and cancer, announced the publication of data from the pivotal Phase 2b ReNeu trial. The study evaluated mirdametinib, an investigational MEK inhibitor, in adult and pediatric patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN). The findings are now available online in the Journal of Clinical Oncology (JCO).
In August 2024, Healx, a clinical-stage biotech company leveraging AI to focus on rare diseases, has secured $47 million in Series C funding. The round was co-led by Silicon Valley’s R42 Group and Atomico, one of Europe’s prominent venture capital firms, with support from new and existing investors such as Balderton, Jonathan Milner, Global Brain, btov, Ayana Capital, o2h, and VU Venture Partners. The funds will be utilized to advance Healx’s pipeline of treatments targeting rare oncology, renal, and neurodevelopmental disorders, including progressing its lead candidate, HLX-1502, into a Phase 2 trial for neurofibromatosis Type 1 (NF1).

Neurofibromatosis Type 2 Overview

Neurofibromatosis Type 2 (NF2) is a rare genetic disorder characterized by the development of noncancerous tumors in the nervous system, primarily affecting the brain and spinal cord. The hallmark of NF2 is bilateral vestibular schwannomas (tumors on the auditory nerves), leading to hearing loss, tinnitus, and balance issues. Other manifestations may include meningiomas, ependymomas, and cataracts. NF2 is caused by mutations in the NF2 gene, which encodes the tumor suppressor protein merlin. It is typically inherited in an autosomal dominant pattern but can also arise from spontaneous mutations. Treatment focuses on symptom management, including surgery, radiation, and targeted therapies.

Get a Free Sample PDF Report to know more about Neurofibromatosis Type 2 Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/neurofibromatosis-2-pipeline-insight

Emerging Neurofibromatosis Type 2 Drugs Under Different Phases of Clinical Development Include:

REC-2282: Recursion Pharmaceuticals
VT3989: Vivace Therapeutics
HLX-1502: Healx Limited
Mirdametinib (PD-0325901): SpringWorks Therapeutics
Selumetinib: AstraZeneca
FCN-159: Fosun Pharmaceutical
NFX-179 Gel: NFlection Therapeutics, Inc.

Neurofibromatosis Type 2 Route of Administration

Neurofibromatosis Type 2 pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Neurofibromatosis Type 2 Molecule Type

Neurofibromatosis Type 2 Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Neurofibromatosis Type 2 Pipeline Therapeutics Assessment

Neurofibromatosis Type 2 Assessment by Product Type
Neurofibromatosis Type 2 By Stage and Product Type
Neurofibromatosis Type 2 Assessment by Route of Administration
Neurofibromatosis Type 2 By Stage and Route of Administration
Neurofibromatosis Type 2 Assessment by Molecule Type
Neurofibromatosis Type 2 by Stage and Molecule Type

DelveInsight’s Neurofibromatosis Type 2 Report covers around 5+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Neurofibromatosis Type 2 product details are provided in the report. Download the Neurofibromatosis Type 2 pipeline report to learn more about the emerging Neurofibromatosis Type 2 therapies

Some of the key companies in the Neurofibromatosis Type 2 Therapeutics Market include:

Key companies developing therapies for Neurofibromatosis Type 2 are – AstraZeneca, Recursion Pharmaceuticals Inc., Vivace Therapeutics, Inc, Novartis Pharmaceuticals, GlaxoSmithKline, Ikena Oncology, SpringWorks Therapeutics, Inc, and others.

Neurofibromatosis Type 2 Pipeline Analysis:

The Neurofibromatosis Type 2 pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Neurofibromatosis Type 2 with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neurofibromatosis Type 2 Treatment.
Neurofibromatosis Type 2 key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Neurofibromatosis Type 2 Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neurofibromatosis Type 2 market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Neurofibromatosis Type 2 drugs and therapies

Neurofibromatosis Type 2 Pipeline Market Drivers

Advances in Genetic Research, Emerging Targeted Therapies, Increased Awareness and Diagnosis, Supportive Regulatory Environment, Collaboration and Funding, are some of the important factors that are fueling the Neurofibromatosis Type 2 Market.

Neurofibromatosis Type 2 Pipeline Market Barriers

However, Rarity of the Disease, Complexity of Tumor Biology, High Costs of Development, Limited Treatment Options, Regulatory Challenges, and other factors are creating obstacles in the Neurofibromatosis Type 2 Market growth.

Scope of Neurofibromatosis Type 2 Pipeline Drug Insight

Coverage: Global
Key Neurofibromatosis Type 2 Companies: Recursion Pharmaceuticals, Vivace Therapeutics, Healx Limited, SpringWorks Therapeutics, AstraZeneca, Fosun Pharmaceutical, NFlection Therapeutics, Inc., and others
Key Neurofibromatosis Type 2 Therapies: REC-2282, VT3989, HLX-1502, Mirdametinib (PD-0325901), Selumetinib, FCN-159, NFX-179 Gel, and others
Neurofibromatosis Type 2 Therapeutic Assessment: Neurofibromatosis Type 2 current marketed and Neurofibromatosis Type 2 emerging therapies
Neurofibromatosis Type 2 Market Dynamics: Neurofibromatosis Type 2 market drivers and Neurofibromatosis Type 2 market barriers

Request for Sample PDF Report for Neurofibromatosis Type 2 Pipeline Assessment and clinical trials

Table of Contents

1. Neurofibromatosis Type 2 Report Introduction

2. Neurofibromatosis Type 2 Executive Summary

3. Neurofibromatosis Type 2 Overview

4. Neurofibromatosis Type 2- Analytical Perspective In-depth Commercial Assessment

5. Neurofibromatosis Type 2 Pipeline Therapeutics

6. Neurofibromatosis Type 2 Late Stage Products (Phase II/III)

7. Neurofibromatosis Type 2 Mid Stage Products (Phase II)

8. Neurofibromatosis Type 2 Early Stage Products (Phase I)

9. Neurofibromatosis Type 2 Preclinical Stage Products

10. Neurofibromatosis Type 2 Therapeutics Assessment

11. Neurofibromatosis Type 2 Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Neurofibromatosis Type 2 Key Companies

14. Neurofibromatosis Type 2 Key Products

15. Neurofibromatosis Type 2 Unmet Needs

16 . Neurofibromatosis Type 2 Market Drivers and Barriers

17. Neurofibromatosis Type 2 Future Perspectives and Conclusion

18. Neurofibromatosis Type 2 Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Neurofibromatosis Type 2 Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Recursion Pharma, Vivace Therapeutics, Healx Limited, SpringWorks Therapeutics

Beauty Industry Unites to Tackle Climate Change with Launch of the Green Pledge

SAN DIEGO – March 24, 2025 – This April, The Green Beauty Community Foundation and Green Spa Network (GSN Planet) proudly introduce the Green Pledge, an industry-wide movement calling upon beauty professionals to take real, measurable actions toward sustainability. Recognizing the urgency of climate-related impacts—from wildfires in California and Carolina, to flooding in Appalachia, and devastating tornadoes—the beauty industry is coming together, driven by a shared commitment to meaningful change.

Backed by industry leaders such as the Professional Beauty Association, Pivot Point International, Innersense Organic Beauty, Americas Beauty Show, Universal Companies, Green Circle Salons, Pact Collective, Sustain Beauty Co., and other dedicated partners, the Green Pledge is a powerful call to action designed to inspire stylists, salons, and brands to implement practical, impactful sustainability practices.

Daniel Johnson, Founder and Executive Director of The Green Beauty Community Foundation, states, “Taking the Green Pledge isn’t about perfection; it’s about progress. We believe that when beauty professionals collaborate, we create lasting change. Our collective efforts empower us to protect our planet, our industry, and our communities.”

How Beauty Professionals Can Participate:

Watch a Short Educational Video: Learn about sustainability in beauty.
Take the Green Pledge: Commit to five straightforward affirmations promoting greener practices.
Receive a Digital Certificate: Demonstrate your commitment to sustainability.
Access the Marketing Toolkit: Gain exclusive tools like social media templates, press releases, and special discounts to communicate your sustainability journey effectively.

Celebrating Sustainability This Earth Month:

Throughout April, the Green Beauty Community is bringing the Green Pledge to life with a robust schedule of events:

Earth Month Kickoff Call (March 24): Join a live community event to launch the Green Pledge.
Live from America’s Beauty Show: Capture live pledges and broadcast industry enthusiasm for sustainability.
Webinar Featuring Shane Price (Green Circle Salons, April 7): Explore sustainability practices deeply embedded within the beauty industry.
Green Spa Network Earth Month Webinar(April 24th): Gain insights from wellness and spa industry leaders.
Community-Generated Content: Beauty professionals will share their sustainability commitments across social media.
Exclusive Education for PBA Members: Free access to Sustainability 101 courses provided during April.

Join the Movement:

We invite brands to become sustainability leaders and play a pivotal role in this transformational initiative:

Amplify the Green Pledge: Share through your channels to unite the industry.
Sponsor the Initiative: Support the nonprofit effort to drive sustainable practices industry-wide.
Contribute to the Green Pledge Toolkit: Provide exclusive discounts, resources, or educational materials.

Brands choosing to participate will receive significant recognition through extensive marketing efforts, gaining visibility among thousands of eco-conscious beauty professionals and consumers.

For more information on sponsorship and participation opportunities, or to request a detailed sponsor deck, please contact:

Daniel Johnson, Founder & Executive Director, The Green Beauty Community Foundation, Email: Daniel@greenbeautycommunity.com, Phone: 619-865-4620 Website: www.greenbeautycommunity.com

Together, let’s make sustainable beauty the new standard.

About The Green Beauty Community Foundation

The Green Beauty Community Foundation is a vibrant, inclusive 501(c)(3) nonprofit organization dedicated to connecting individuals and brands who share a passion for sustainable beauty. We strive to inspire, educate, and empower our members to make informed choices that celebrate beauty & wellness while respecting our planet.

Media Contact:

Daniel Johnson, Email: Daniel@greenbeautycommunity.com, Phone: 619-865-4620

Media Contact
Company Name: The Green Beauty Community Foundation
Contact Person: Daniel Johnson
Email: Send Email
Phone: 619-865-4620
Country: United States
Website: www.greenbeautycommunity.com

Automotive Innovator Hosam Al-Baderi Shares Insights in Exclusive Online Interview

Hosam Al-Baderi, the CEO of Amari Motors and Amari Customs and Designs, recently shared his journey and professional insights in a detailed online interview, offering an in-depth look at the intersections between his passions and his entrepreneurial ventures in the automotive industry.

In the interview, Al-Baderi discusses his roots in Salt Lake City, Utah, where he developed an early interest in sports and outdoor activities that eventually paved the way for his career in automotive excellence. From humble beginnings, his businesses have grown into well-respected entities in the realm of custom and luxury automobiles. The interview delves into his personal philosophy, business strategies, and the innovative integration of design principles from aviation to automotive projects.

Al-Baderi also discusses the importance of continuous learning and adaptation, which he credits for his ability to stay ahead in a rapidly evolving industry. His approach to overcoming challenges and leveraging opportunities for growth provides valuable lessons for aspiring entrepreneurs and business leaders alike.

“This interview is a fantastic opportunity for car enthusiasts and budding entrepreneurs to get a closer look at what it takes to succeed in the competitive world of automotive customization and restoration,” said Jane Doe, Public Relations Manager at Amari Motors. “Hosam’s commitment to excellence and innovation shines through every project at Amari Motors and Amari Customs and Designs.”

The interview also highlights Al-Baderi’s commitment to philanthropy, reflecting his deep-rooted belief in giving back to the community that supports his ventures. His contributions to various charitable causes demonstrate a model of entrepreneurship that values both success and social responsibility.

The provides a compelling view of how personal passions can transform into successful business ventures that push industry boundaries and set new standards.

To read the full interview with Hosam Al-Baderi, visit the website here.

About Amari Motors:

Amari Motors, along with its sister company Amari Customs and Designs, specializes in the buying, selling, and customization of high-end automobiles. Founded by Hosam Al-Baderi, the companies are renowned for their dedication to quality, innovation, and customer satisfaction, making them leaders in the luxury automotive market.

Media Contact
Contact Person: Hosam Al-Baderi
Email: Send Email
City: Salt Lake City
State: Utah
Country: United States
Website: https://www.hosamalbaderi.com/

Peggy’s Home Care Continues Transforming Lives with Expert Home Care in Santa Cruz

Providing compassionate home care services to ensure peace of mind for families in Santa Cruz

Santa Cruz, CA – Peggy’s Home Care reaffirms its commitment to delivering exceptional, personalized home care services in Santa Cruz, ensuring families have trusted caregivers to support their loved ones. Focusing on expert and compassionate care, Peggy’s Home Care addresses the growing demand for reliable home care in Santa Cruz. It continues to make a difference in the lives of families and seniors in the area.

“At Peggy’s Home Care, we understand the importance of peace of mind for families who entrust us with their loved ones. Our caregivers bring professionalism and warmth, offering services that meet physical needs and enhance emotional well-being,” said Sadie Kvenild, owner of Peggy’s Home Care. “We are honored to be part of the Santa Cruz community and remain steadfast in our mission to deliver quality care that empowers seniors to live independently and with dignity in their homes.”

As the demand for experienced home care caregivers in Santa Cruz increases, Peggy’s Home Care stands out with its tailored approach to meeting individual needs. From assistance with daily activities to specialized care for chronic conditions, the agency is dedicated to fostering independence, safety, and comfort for seniors. Their services cater to various care requirements, ensuring families can confidently rely on their expertise.

Home care offers a unique advantage by allowing seniors to remain in the comfort and familiarity of their homes while receiving the support they need. This setup promotes emotional well-being and minimizes the risks associated with transitioning to an unfamiliar environment, such as stress, anxiety, or confusion. Peggy’s Home Care provides seniors with personalized care plans tailored to their specific needs, ensuring they maintain their independence and quality of life.

Families who opt for home care also benefit from the peace of mind that comes with knowing their loved ones are in the hands of qualified professionals. Unlike institutional care settings, where caregiver attention may be divided among multiple patients, Peggy’s Home Care focuses on one-on-one support. This personalized approach ensures caregivers form meaningful connections with clients, addressing their physical and emotional needs.

Moreover, home care is often a more cost-effective solution compared to long-term care facilities. Peggy’s Home Care offers customizable service options for families seeking flexibility, ranging from part-time assistance to round-the-clock care. This adaptability makes it easier for families to find a care plan that fits their budget and their loved ones’ needs without compromising quality or reliability.

For more information about Peggy’s Home Care and their home care in Santa Cruz, please visit their website at https://peggyshomecare.com

About Peggy’s Home Care:

Peggy’s Home Care is a premier provider of in-home care services in Santa Cruz, CA. With a reputation built on trust and excellence, the agency delivers personalized care solutions that empower seniors to live fulfilling lives at home. Through a dedicated team of caregivers, Peggy’s Home Care continues to enhance the well-being of individuals and families by offering services that prioritize compassion, reliability, and expertise.

Media Contact
Company Name: Peggy’s Home Care
Contact Person: Sadie Kvenild
Email: Send Email
Phone: +1 831 659 5887
Address:851 Munras Ave
City: Monterey
State: CA
Country: United States
Website: https://peggyshomecare.com/

Hearts At Home Elevates Home Health Care Standards for Seniors in Norman, OK

Continuing its legacy of trusted Norman senior home care, Hearts At Home brings families reliable, compassionate solutions for elderly care needs.

Norman, OK – Hearts At Home, a dedicated provider of senior home health care, announced its continued commitment to improving the quality of life for seniors in Norman, OK. Responding to the growing need for dependable home health care services, Hearts At Home provides comprehensive solutions tailored to each individual’s needs. Their mission centers on helping families achieve peace of mind while ensuring seniors live with dignity and comfort in their homes.

“At Hearts At Home, our commitment to the Norman community is unwavering,” said Marcia Crook, owner of Hearts At Home Senior Care. “We understand the unique challenges families face in caring for their loved ones, and we’re here to ensure seniors receive exceptional care designed to enrich their lives. Our approach prioritizes trust, compassion, and quality service tailored to individual needs.”

This announcement underscores the growing demand for home health care services in Norman as families seek professional caregivers for their aging relatives. By offering assistance with daily living, medical coordination, and emotional support, Hearts At Home continues to be a trusted partner for those navigating senior care challenges.

Home health care is a lifeline for many seniors and their families. It offers the invaluable benefit of allowing elderly individuals to remain in the comfort of their own homes while receiving the care they need. This familiar environment fosters emotional well-being and reduces the stress often associated with transitioning to assisted living or nursing facilities.

One significant advantage of home health care is its personalized approach. Unlike institutional settings, home health care plans are tailored to meet the unique needs of each individual. Whether it’s assistance with daily activities, specialized medical care, or emotional companionship, families can trust that their loved ones receive one-on-one attention from skilled caregivers.

Additionally, home health care supports families by providing flexible scheduling and professional expertise. With trained caregivers handling day-to-day tasks, families are relieved of the pressures of caregiving, enabling them to focus on maintaining strong and meaningful relationships with their loved ones. This holistic approach ensures physical well-being and emotional and social enrichment for seniors.

Families searching for reliable Norman senior home care in Norman, OK, can count on Hearts At Home for their loved ones’ well-being. For more information about Hearts at Home and their home health care in Norman, please visit their website at https://heartsathomeok.com.

About He:

Hearts At Home Senior Care is a premier provider of home health care services in Norman, OK. The company’s dedicated team of professional caregivers focuses on delivering personalized, compassionate care to seniors. From assistance with daily activities to more complex medical support, Hearts At Home strives to make a meaningful difference in the lives of seniors and their families.

Media Contact
Company Name: Hearts at Home Companion Care
Contact Person: Marcia Crook
Email: Send Email
Phone: (405) 310-4000
Address:1400 N Porter Ave
City: Norman
State: OK
Country: United States
Website: https://heartsathomeok.com

Proteomics Market to Hit $67.22 Billion by 2029, A 2X Growth Projected in the Next 6 Years – Arizton

“Proteomics Market Research Report by Arizton”

According to Arizton’s latest research report, the global proteomics market is growing at a CAGR of 12.94% during 2023-2029.

Looking for More Information? Click: https://www.focusreports.store/report/proteomics-market

Report Scope:             

Market Size (2029): $67.22 Billion 

Market Size (2023): $32.39 Billion 

CAGR (2023-2029): 12.94% 

Historic Year: 2020-2022

Base Year: 2023 

Forecast Year: 2024-2029 

Market Segmentation: Product, Applications, End-Users, and Geography

Geographical Analysis: North America, Europe, APAC, Latin America, And Middle East & Africa 

Personalized Medicine: Shaping the Future of Healthcare with Proteomics

Personalized medicine, or precision medicine, tailors treatments to an individual’s unique molecular profile, genetics, lifestyle, and environment, offering more effective and cost-efficient healthcare solutions. Proteomics, the study of proteins, plays a crucial role in this approach by helping identify biomarkers and develop new drugs. The US FDA recognizes proteomics as essential for personalized medicine, with 95% of FDA-approved drugs targeting proteins and most diagnostic tests relying on protein analysis. The number of personalized medicines on the market has doubled from 132 in 2019 to over 280 in 2021. Notable examples include Genentech’s T-Dxd drug for HER2-positive breast cancer and Quanterix’s CardioMetRx test for heart failure. Collaborations like Azenta, Inc.’s partnership with FinnGen in 2024, further emphasize the growing importance of proteomics in personalized medicine. This expanding focus on proteomics is driving significant market growth and the demand for more tailored healthcare solutions.

Competitive Landscape of the Global Proteomics Market

The global proteomics market is highly competitive, with several leading players dominating the industry, alongside emerging companies challenging large and medium-sized market leaders. Agilent Technologies, Bio-Rad Laboratories, Thermo Fisher Scientific, and BGI Genomics are some of the key players, collectively holding a significant share of the market. These companies continually expand their proteomics solutions and services to meet client needs and comply with international regulations while improving product efficiency and strengthening their market presence.

Key strategies such as partnerships and collaborations have intensified market competition, allowing major players to expand their capabilities and increase revenue shares. Rapidly growing vendors like Danaher and PerkinElmer are also making notable strides, thanks to their global reach, diversified portfolios, and strong focus on innovation and research. These factors contribute to their growing influence in the market, shaping the future of proteomics.

Vendors’ Recent Activities & Developments

In 2024, Thermo Fischer Scientific announced the acquisition of Olink Holding AB, a pioneer in next-generation proteomics solution development. Olink’s expertise lies in advanced proteomics discovery and development, supporting both academic institutes and biopharma companies.
In 2023, SomaLogic, one of the leading companies in data-driven proteomics technology, and Standard BioTools Inc. announced that they had entered into a definitive agreement to combine in an all-stock merger.
In 2023, Danaher acquired Abcam, one of the leading companies in the proteomics market, for around $5.7 billion. Abcam offers tools and reagents for diagnostic, drug discovery, and scientific research, including proteomics.
In 2023, Bruker Corporation and Biognosys AG announced a strategic partnership. Under this partnership, Biognosys will lead proteomics and proteogenomic CRO services and will access Bruker’s leading 4D proteomics timsTOF technology for high-precision proteomics development.

North America’s Dominance in the Global Proteomics Market

In 2023, North America held the largest market share of over 33% in the global proteomics market, with the US contributing 93% and Canada 7%. The region is expected to grow at a healthy CAGR of 12.51% during the forecast period. This growth is driven by the rising prevalence of chronic diseases such as cancer, cardiovascular diseases, diabetes, and genetic disorders, which fuel the demand for personalized medicine. With 2.1 million cancer patients, 40 million people living with diabetes, and 22 million CVD cases, there is significant demand for personalized treatments, early diagnosis, and R&D in proteomics.

The US has seen significant advancements in personalized medicine, driven by high healthcare expenditure, easy access to treatments, and increasing demand for proteomics in drug development. The region’s biotech and pharmaceutical sectors, with their growing focus on biomarker discovery, are also creating a strong demand for proteomics services. This trend is expected to continue, making drug discovery and personalized medicine key drivers of proteomics growth in North America.

Explore More: https://www.focusreports.store/report/proteomics-market

Vendors List

Agilent Technologies
Bio-Rad Laboratories 
Thermo Fisher Scientific
Danaher 
PerkinElmer 
BGI Group
Bruker
DiaSorin
HORIBA
Illumina
INOVIQ
LI-COR Biosciences
Nautilus Biotechnology
Proteome Factory
QIAGEN
Rhythm Biosciences
Shimadzu Scientific Instruments
Seer
Waters
Charles River Laboratories
Applied Biomics
Creative Proteomics
Poochon Scientific
SomaLogic
Vproteomics
AnteoTech
Biognosys
GeNei
Grace Bio-Labs
ITSI-BIO
MSAID
Olink
Proteomics International
Quanterix
Alamar Biosciences
Nicoya Lifesciences
Promega

Segmentation & Forecast

Product

Consumables & Reagents
Instrument & Software
Services

Applications

Drug Discovery & Development and Translational Research
Clinical Applications 
Forensic and Applied Proteomics

End-users

Pharma & Biotech Companies
Academic & Research Institutes/Laboratories
Hospitals
Diagnostics Labs and Forensic Labs

Geography

North America

The US
Canada

Europe

Germany
France
The UK
Italy
Spain

APAC

Japan
China
India
South Korea
Australia

Latin America

Brazil
Mexico
Argentina

Middle East & Africa

Turkey
South Africa
Saudi Arabia

What Key Findings Our Research Analysis Reveals?             

How big is the global proteomics market?

What are the factors driving the global proteomics market growth?

What is the growth rate of the global proteomics market?

Who are the major players in the global proteomics market?

Which region will have the highest growth in the global proteomics market?

Check Out Some of the Top Selling Reports of Your Interest:          

Global Hospital Beds Market – Focused Insights 2024 – 2029

https://www.focusreports.store/report/global-hospital-beds-market-focused-insights

Global Enteral Feeding Devices Market – Focused Insights 2024 – 2029

https://www.focusreports.store/report/global-enteral-feeding-devices-market-focused-insights

Why Arizton?                                     

100% Customer Satisfaction                                     

24×7 availability – we are always there when you need us                                     

200+ Fortune 500 Companies trust Arizton’s report                                     

80% of our reports are exclusive and first in the industry                                     

100% more data and analysis                                     

1500+ reports published till date                   

Post-Purchase Benefit                                 

1hr of free analyst discussion                                 
10% off on customization

About Us:                                                                          

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.  

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.                                                                               

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1 3122332770
Country: United States
Website: https://www.arizton.com/market-reports/proteomics-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Proteomics Market to Hit $67.22 Billion by 2029, A 2X Growth Projected in the Next 6 Years – Arizton

The Future of Tech: AI x Web3 – A Convergence of Innovation and Opportunity

The future of technology took center stage as Orbis86 successfully hosted “The Future of Tech: AI x Web3” during ETH SF in San Francisco on March 13, 2025. Title-sponsored by Hedera, the event brought together some of the brightest minds in AI and Web3 for an evening of insights, networking, and live demos — showcasing the next wave of digital transformation.

Excitement crackled through the air as industry leaders, innovators, and disruptors engaged in thought-provoking panel discussions, sponsor presentations, and startup demos. The space pulsed with dynamic conversations — from deep discussions to immersive startup showcases. The event not only highlighted the transformative potential of AI and Web3 but also fostered meaningful connections among key players shaping the industry’s future. What happens when some of the brightest minds in AI and Web3 come together under one roof? Let’s dive into the highlights.

A Powerhouse Lineup of Speakers

The evening buzzed with anticipation as industry leaders took the stage to explore the future of AI and Web3. Moderated by Ken Nim, Co-Founder of OffChain Global, the discussion brought together an impressive panel of experts. Brett Bunnell (Business Attorney and Co-Chair at Cole-Frieman & Mallon LLP) navigated the legal complexities of emerging technologies, whileSanjeev Birari (Co-Founder and CBO, Zoniqx) highlighted blockchain’s transformative role in finance. Suzanne Leigh (Chief Editor and Communications Director, Omnity Network) emphasized the power of community in Web3 adoption, and John Occhipinti (Partner, Nautilus) shared an investor’s perspective on AI-driven innovation.

With their deep expertise and forward-thinking insights, the speakers captivated the audience, setting the stage for an evening of thought-provoking discussions on the technologies shaping our future.

Key Highlights

Spotlight on Visionary Sponsors

The evening began with a deep dive into the contributions of our esteemed sponsors, each playing a vital role in shaping a decentralized future. Hedera showcased its advancements in sustainable Distributed Ledger Technology, while ICP pushed the boundaries of digital innovation. Unstoppable Domains championed the evolution of user-controlled digital identity and Cole-Frieman & Mallon LLP introduced next-generation financial solutions. These weren’t just presentations; they were bold visions that framed the night’s discussions.

Engaging Panel Discussion

As the event gained momentum, expert-led panel discussions explored the evolving landscape of AI and Web3. Industry leaders tackled pressing topics—from regulatory challenges to real-world adoption—offering invaluable insights. The audience wasn’t just passively listening; they were actively engaged, sparking debates and deepening their understanding of this rapidly evolving space. These conversations weren’t just informative; they served as catalysts for meaningful change.

Live Startup Demos: Where AI Meets Web3

Attendees got an exclusive look at groundbreaking projects from emerging startups. Orbiter Finance and other innovative ventures like Blocksee, 384.co, RugPool, and Synexis showcased live demos, demonstrating how AI and blockchain are converging to unlock new market opportunities. The interactive format allowed attendees to engage directly with founders and explore potential collaborations.

Networking Mixer: Where Connections Sparked Innovation

As the evening unfolded, attendees engaged in high-energy networking at our exclusive Networking Mixer, where Web3 thought leaders, investors, and pioneers connected over a glass of wine or a cold beer. Conversations flowed effortlessly, sparking new collaborations and groundbreaking ideas in the evolving AI and Web3 space. To elevate the experience, attendees were treated to a complimentary cup of premium hot cacao from Agroverse, adding a warm and delightful touch to the night’s vibrant atmosphere.

As the excitement built throughout the evening, we took things up a notch with a special giveaway that celebrated the decentralized future.

Exclusive Giveaway: 100 Premium Web3 Domains Up for Grabs!

To make the evening even more exciting, Orbis86 hosted a special giveaway featuring Web3 domains from Unstoppable Domains—100 Web3 domains, each valued at $50! Attendees had the chance to claim their own domain, empowering them to establish a stronger digital identity in the decentralized world.

We extend our sincere gratitude to our sponsors, co-host, and partners for their invaluable support in making this event a success. Their commitment to fostering innovation in Web3 continues to drive the industry forward.

With that, let’s introduce our key sponsors and partners, who played a pivotal role in making this event a success.

Sponsors

Hedera– Title Sponsor: Hedera is an open-source, leaderless, proof-of-stake public ledger that supports a robust ecosystem built by a global community. The Hedera network is governed by a diverse council of industry leaders including abrdn, Avery Dennison, Boeing, Chainlink Labs, DBS Bank, Dell Technologies, Google, IBM, LG Electronics, Tata Communications, Ubisoft, Wipro, and more, including prestigious academic institutions like The London School of Economics and University College London.

Cole-Frieman & Mallon LLP (CFM) – Venue Sponsor: Cole-Frieman & Mallon LLP is a top-tier investment management law firm, providing innovative legal solutions for financial services. Serving start-ups to multibillion-dollar funds, CFM specializes in fund formation, regulatory compliance, counterparty documentation, and employment matters. Renowned for its expertise in digital asset funds, CFM also advises on corporate matters and intellectual property (IP) matters, including fundraising, M&A, governance, tax, and compliance. The firm publishes the Hedge Fund Law Blog, a key resource for industry insights.

Internet Computer (ICP) – Sponsor: ICP is revolutionizing Web3 with its fully on-chain platform, eliminating reliance on corporate clouds, insecure bridges, and expensive oracles. It supports scalable, tamper-proof decentralized applications for social media, enterprise systems, and more, ushering in the next era of internet innovation.
Unstoppable Domains – Sponsor: Unstoppable Domains is pioneering the future of user-owned identities through Web3 domains. These blockchain-based domains empower individuals with full control over their data, eliminating reliance on traditional centralized systems. More than just web addresses, these domains function as a cornerstone of Web3 identity, enabling seamless logins, simplified crypto payments, and true ownership of online presence.

Host

Orbis86: Orbis86 is revolutionizing Web3 innovation through its Engage–Educate–Elevate approach, engaging users with personalized experiences, educating them on emerging technologies, and elevating their journey with seamless cross-chain integration. Throughout the year, we host global events that bring communities together to explore Web3 and AI, enabling meaningful discussions and collaboration. Our mission is to create an inclusive ecosystem where individuals can learn, grow, and shape the future of decentralized technology.

Co-host

OffChain: OffChain is a global community that brings together Web3 professionals and enthusiasts. With over seventy chapters worldwide, OffChain welcomes everyone—from blockchain developers and crypto VCs to miners, quant traders, and even casual Bitcoin holders. OffChain chapters hold regular, casual social gatherings, occasionally incorporating speaking events to facilitate meaningful dialogue.

Event Partners:

BrandPR, a specialized PR and marketing agency, has joined forces with Orbis86 to elevate Web3 brands on a global scale. Since 2022, BrandPR has been helping crypto and Web3 projects gain the recognition they deserve through top-tier media coverage and cutting-edge community-building strategies.
ICP HUBS Network is a worldwide initiative advancing education, adoption, and innovation for ICP. The HUBs bring together developers, investors, and Web3 pioneers to collaborate, learn, and shape the decentralized future.
Quantum Leap Labs is the official accelerator for ICP HUBS Canada & US. It fuels Web3 innovation by equipping founders with mentorship, funding, and strategic resources to scale transformative projects on the Internet Computer.
Agroverse, a TrueSight DAO initiative, is dedicated to restoring 10,000 hectares of the Amazon rainforest by empowering organic cacao farmers to reforest previously degraded land. This mission promotes ecological renewal and sustainable livelihoods.

Media Partners

A Defining Moment for AI and Web3

“The Future of Tech: AI x Web3” was more than just an event—it was a glimpse into the future of digital innovation. The insights, connections, and ideas shared during the evening are set to drive real-world impact in the evolving AI and Web3 landscape.

A special thank you to our sponsors, partners, and media collaborators for making this event a resounding success. Your support and vision are shaping the future of AI and Web3.

Stay tuned for upcoming Orbis86 events as we continue to lead the future of technological transformation!

Media Contact
Company Name: 8ty6.co
Contact Person: Public Relations
Email: Send Email
Phone: 408.253.4000
Address:San Jose
City: Milpitas
State: California
Country: United States
Website: https://orbis86.com/?utm_source=orbis86&utm_source=Orbis86%20-PR